288 related articles for article (PubMed ID: 31451931)
21. Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms.
Berardi R; Torniai M; Partelli S; Rubini C; Pagliaretta S; Savini A; Polenta V; Santoni M; Giampieri R; Onorati S; Barucca F; Murrone A; Bianchi F; Falconi M
PLoS One; 2018; 13(5):e0197035. PubMed ID: 29787601
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
23. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
[TBL] [Abstract][Full Text] [Related]
24. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M
J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
[TBL] [Abstract][Full Text] [Related]
25. Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.
Couvelard A; Pélaprat D; Dokmak S; Sauvanet A; Voisin T; Couvineau A; Ruszniewski P
Pancreas; 2017; 46(5):631-638. PubMed ID: 28375946
[TBL] [Abstract][Full Text] [Related]
26. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
28. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.
Kaemmerer D; Schindler R; Mußbach F; Dahmen U; Altendorf-Hofmann A; Dirsch O; Sänger J; Schulz S; Lupp A
BMC Cancer; 2017 Dec; 17(1):896. PubMed ID: 29282035
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies.
Werner C; Dirsch O; Dahmen U; Grimm MO; Schulz S; Lupp A
Transl Oncol; 2020 Sep; 13(9):100801. PubMed ID: 32460182
[TBL] [Abstract][Full Text] [Related]
30. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.
Papotti M; Kumar U; Volante M; Pecchioni C; Patel YC
Clin Endocrinol (Oxf); 2001 May; 54(5):641-9. PubMed ID: 11380495
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.
de Herder WW; Hofland LJ; van der Lely AJ; Lamberts SW
Endocr Relat Cancer; 2003 Dec; 10(4):451-8. PubMed ID: 14713257
[TBL] [Abstract][Full Text] [Related]
33. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
34. Intervention in gastro-enteropancreatic neuroendocrine tumours.
Baudin E; Planchard D; Scoazec JY; Guigay J; Dromain C; Hadoux J; Debaere T; Elias D; Ducreux M
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):855-65. PubMed ID: 23582924
[TBL] [Abstract][Full Text] [Related]
35. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
[TBL] [Abstract][Full Text] [Related]
36. Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression.
Pereira SS; Pereira R; Santos AP; Costa MM; Morais T; Sampaio P; Machado B; Afonso LP; Henrique R; Monteiro MP
Pathology; 2019 Oct; 51(6):593-599. PubMed ID: 31466863
[TBL] [Abstract][Full Text] [Related]
37. Peptide receptors in gut endocrine tumours.
de Herder WW; Hofland LJ; van der Lely AJ; Lamberts SW
Baillieres Clin Gastroenterol; 1996 Dec; 10(4):571-87. PubMed ID: 9113313
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
[TBL] [Abstract][Full Text] [Related]
39. [Quantitative analysis and significance of CXCL12 and CXCR4 expression with lymphangiogenesis of pancreatic adenocarcinoma].
Fei LM; Wang CL; Zhao WH; Cui K; Zhang B; Zhou WY; Zhong WX; Li S
Zhonghua Wai Ke Za Zhi; 2009 May; 47(10):783-6. PubMed ID: 19615218
[TBL] [Abstract][Full Text] [Related]
40. Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease.
Wehler T; Wolfert F; Schimanski CC; Gockel I; Herr W; Biesterfeld S; Seifert JK; Adwan H; Berger MR; Junginger T; Galle PR; Moehler M
Oncol Rep; 2006 Dec; 16(6):1159-64. PubMed ID: 17089032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
